Gruber Rolf W, Roehrig Bernd
Pediatric Surgery Department, Klinikum Mutterhaus, Trier, Germany.
J Neurosurg Pediatr. 2010 Jan;5(1):4-16. doi: 10.3171/2008.7.17690.
This 25-year follow-up study was performed on 120 children with hypertensive hydrocephalus to evaluate the influence of the early prophylactic implantation of the Integra antisiphon device (ASD, Integra Neurosciences Ltd.) on the rate of proximal shunt obstructions and the frequency of symptomatic slit ventricle syndrome (SVS). The adaptability of the ASD to growth, proper positioning of the ASD as a necessity for its successful performance, and the 3 phases of SVS development are discussed.
Since 1978, the ASD has consistently been implanted either at the time of primary shunt insertion (66 neonates, mean follow-up 11 years) or during revisions of preexisting shunts (54 children, mean follow-up 11.8 years). The complication rate among the 54 children before ASD implantation (mean follow-up 8.3 years) was compared with that among all 120 patients once an ASD had been inserted. Shunt complications were documented as ventricular catheter, distal catheter, and infectious complications.
The study revealed a significant long-term reduction in ventricular catheter obstructions and hospitalizations due to intermittent intracranial hypertension symptoms (symptomatic SVS) after both primary and secondary ASD implantation. Data in the study suggest that the high rate of ventricular catheter obstruction in pediatric shunt therapy is caused by hydrostatic suction induced by differential-pressure valve shunts during mobilization of the patient and that the development of a SVS can be traced back to this constant suction, which causes chronic CSF overdrainage and ventricular noncompliance. Recurrent ventricular catheter obstruction and SVS can be prevented by prophylactic supplementation of every shunt system with an ASD.
To inhibit chronic hydrostatic suction, to prevent overdrainage and proximal shunt obstruction, and to avoid SVS and thus improve the patient's quality of life, the prophylactic implantation of an ASD in every pediatric hydrocephalus shunt is recommended.
本项为期25年的随访研究针对120例高血压性脑积水患儿开展,旨在评估早期预防性植入Integra抗虹吸装置(ASD,Integra神经科学有限公司)对近端分流梗阻发生率及症状性裂隙脑室综合征(SVS)发生频率的影响。讨论了ASD对生长的适应性、ASD正确定位对其成功发挥作用的必要性以及SVS发展的三个阶段。
自1978年以来,ASD一直是在初次分流植入时(66例新生儿,平均随访11年)或对现有分流进行翻修时(54例儿童,平均随访11.8年)植入。将54例患儿在植入ASD前(平均随访8.3年)的并发症发生率与所有120例植入ASD后的患者的并发症发生率进行比较。分流并发症记录为脑室导管、远端导管和感染性并发症。
研究显示,初次和二次植入ASD后,脑室导管梗阻及因间歇性颅内高压症状(症状性SVS)导致的住院情况均有显著的长期减少。研究数据表明,小儿分流治疗中脑室导管梗阻发生率高是由患者活动期间压差阀分流引起的静水压抽吸所致,且SVS的发展可追溯至这种持续抽吸,其导致慢性脑脊液过度引流和脑室顺应性降低。通过在每个分流系统中预防性补充ASD可预防复发性脑室导管梗阻和SVS。
为抑制慢性静水压抽吸,预防过度引流和近端分流梗阻,避免SVS从而改善患者生活质量,建议在每例小儿脑积水分流中预防性植入ASD。